Stem cell dopamine cell transplant safe in Parkinson trial

A landmark clinical trial has demonstrated the safety and feasibility of transplanting stem cell-derived dopamine-producing cells into the brains of patients with Parkinson’s disease, marking a significant step toward a potential restorative therapy. The Phase III STEMPD trial, led by researchers from Lund University and Skåne University Hospital in Sweden, involved eight patients and reported no serious side effects linked to the transplanted cells during the first year of follow-up. The findings were published in the journal Nature Medicine and presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting.

Parkinson’s disease is characterized by the progressive loss of dopamine-producing neurons in the brain, leading to symptoms such as tremor, stiffness, and slowness of movement. Current treatments primarily involve medications that replace dopamine but do not halt disease progression and often become less effective over time. The STEMPD trial tested a cryopreserved, off-the-shelf dopaminergic progenitor cell product derived from human pluripotent stem cells, designed to replace the lost neurons and restore dopamine production.